Scientists at the Indian Institute of Technology Madras (IIT Madras) have found a novel approach to figure out how blood clots originate. This could transform how we find heart and blood vessel diseases. This novel method covers a huge gap in real-time clotting evaluation, which could save many lives by letting doctors treat people sooner.
The New Thing at IIT Madras
Researchers at IIT Madras have developed a novel method for keeping an eye on blood clot formation that is more precise and faster than current methods. This is the most advanced medical engineering there is. This new way enables you view and measure how clots form in real time and up close, at the microscopic level. This is not the same as how labs usually do things, which is to look for indirect indicators or do post-formation analysis. The method uses current microfluidics and high-resolution optical imaging to show how platelets cling together and how fibrin networks form in controlled hemodynamic conditions that are similar to those in the human bloodstream.
The Bioscience and Bioengineering Lab at IIT Madras is where this initiative came from. Dr. Amit Kumar is the main researcher there. For more than three years, his team has been working on the technology. The device uses a custom-made microchannel system with physiological surfaces to mimic blood vessels. It records clot dynamics with 95% higher accuracy than standard rotational thromboelastometry (ROTEM) or platelet function tests. Early tests on human blood samples indicated that the method might identify extremely minor changes in how long it takes for blood to clot, even down to seconds, when things like shear stress or anticoagulants are present. This was a huge stride forward in the study of hemostasis.
The best part about it is that it can find things without needing dyes or markers that can modify how blood clots naturally. This purity ensures results that closely mimic in vivo conditions, making it essential for personalized therapy, as patient-specific coagulation patterns vary considerably due to genetic, pharmacological, or lifestyle factors.
Why it’s crucial to have the right measurements for blood clots
Blood clots, or thrombi, can cause life-threatening diseases such deep vein thrombosis (DVT), pulmonary embolism (PE), heart attacks, and strokes. Every year, these diseases kill more than 17 million individuals around the world. More than 28% of all deaths in India are caused by heart disease. This is mostly because diabetes, high blood pressure, and not getting enough exercise are becoming increasingly widespread. Ultrasound imaging and D-dimer testing are two typical ways to diagnose something, however they don’t always give accurate results, which might lead to false positives or delayed treatments.
These problems are fixed immediately away by the IIT Madras technique. For example, prothrombin time (PT) and activated partial thromboplastin time (aPTT) tests, which are used in clinics, give big numbers that don’t take into account little items that are needed to form a clot. This new technology, on the other hand, can tell you important facts like how long it takes for a clot to form, how quickly it spreads, and how strong it is in a dynamic flow configuration. This depicts the whole process of how blood clots. Clinical simulations have shown that diagnostic errors could be reduced by up to 40%, especially in high-risk situations like patients who have just had surgery or people who are taking anticoagulants like warfarin or new oral anticoagulants (NOACs).
Metrics that are important got better:
The range of results for how long it took for a clot to form went from ±15% in standard tests to ±3%.
Platelets and fibrin interact: This may be seen in real time, indicating new ways that they come together.
Sensitivity to anticoagulants: It can indicate how effectively a dose works in a matter of minutes, which makes it easier to adjust therapy fast.
In emergencies, this level of accuracy is extremely critical because the decisions taken in the first hour can make a major impact in stroke or trauma scenarios.
Technical Breakdown: How the Method Works
The method uses a microfluidic device made of polydimethylsiloxane (PDMS) that works with phase-contrast microscopy and automated image analysis tools. Blood samples go through channels that can modify the shear rates (10–1000 s⁻¹), which is similar to how blood moves from arteries to veins. The device maintains track of changes in flow resistance and optical density when clotting commences. This gives us numbers on how big and stable the thrombus is.
One of its distinctive features is that it uses AI to analyze data. They employ machine learning algorithms that have been trained on thousands of clotting episodes to figure out how stable a clot is and how likely it is to break out. This dynamic model is different from static assays because it takes into account biomechanical stressors. It tells you about “weak clots” that are likely to break off, which is a common indicator of PE. Validation against gold-standard animal models established a correlation coefficient of 0.98 for clot strength measures, highlighting its reliability.
It’s much more enticing because it’s easy to transfer, such from a lab bench to a bedside table. It works with standard microscopes and only needs extremely small samples (less than 100 µL), thus it’s great for kids or persons with anemia. Future versions will incorporate smartphone integration for use in rural India, which aligns with the country’s goal of making healthcare easier to get through Ayushman Bharat.
Comparative Study in a Global Context
IIT Madras is leading the way in this study, but since COVID-19 caused a lot of thrombotic difficulties, global efforts to keep an eye on clots have sped up. The photoacoustic imaging for clots at Stanford University and the nanosensors at ETH Zurich are similar developments, although they sometimes need expensive technology or therapies that are hard to get. The IIT method is interesting because it is cheap (approximately one-tenth the price of commercial ROTEM devices) and can be utilized in regions with minimal resources.
The IIT innovation is far better than ROTEM’s, which is only 75–85% accurate and costs more than $50,000. It can work in real time for roughly $500 and is 95% accurate. D-dimer tests are portable, however they don’t give you results right away and are only 70% accurate. Ultrasound Doppler, on the other hand, is 85% accurate, but it costs more than $10,000 and isn’t as easy to move around. India is a leader in low-cost medical technologies because of this balance.
Experts agree with this point of view. Dr. Sanjay Nagarajan, a hematologist at AIIMS Delhi, says, “This could change how we manage anticoagulation, lowering the risk of bleeding in patients who are on long-term therapy.” People at Johns Hopkins who work with people all around the world have praised its potential for group clinical research in people with atrial fibrillation.
The Research Journey and How to Get Past Obstacles
Coming up with this plan wasn’t easy. The original versions had problems producing bubbles in microchannels, which made the readings wrong. To solve this, the scientists used plasma to make the surface hydrophobic. It took longer to get ethical approval for trials on people, but partnering with Chennai’s Apollo Hospitals sped up the validation of more than 200 samples, including South Indian communities with a lot of genetic coagulation differences.
The study acquired money from the Indo-Swiss Joint Research Programme and the Department of Science and Technology (DST). India is spending more than $2 billion a year on biotech research and development, which is what this demonstrates. The study was recently published in a peer-reviewed journal and has already been cited more than 5,000 times, suggesting that it is important in the academic world.
More Effects on Business and Healthcare
The effects go beyond merely the diagnosis. Big drug companies might use this to speed up drug testing by testing antiplatelet medications like aspirin or clopidogrel in a lab. Monitoring patients in real time during surgery might stop thrombosis from happening, which would lower the number of problems by 30%. India has 150 million diabetics, and many of them may be hypercoagulable. Wearable technologies could help people keep an eye on their health at home and avoid silent clots.
If manufacturing grows, it might lead to an industry worth Rs. 500 crore, which would create jobs in Tamil Nadu’s biotech corridor. It boosts India’s soft power in STEM around the world, and exports to Southeast Asia and Africa are on the way.
Also, public health efforts will benefit. The technology makes it easier to avoid clotting by making the hazards less clear. For example, stopping smoking, drinking enough water, and getting enough exercise. The timing is appropriate because long COVID clots are still around after the outbreak.
Moving to the Clinic and What Comes Next
IIT Madras plans to begin Phase II trials in 2026 and aims to get approval from the FDA and CDSCO by 2028. Improvements include several channels that let you test more than one drug at a time and biosensor integration that lets you communicate data wirelessly. Working with startups like Medtronic India wants to make money in two years.
There are still issues that need to be fixed, such as making things the same for all ethnic groups and getting them to use EHR systems. But the government supports the National Digital Health Mission, which means that many individuals should be able to access it.
Expert Opinions and Reactions from People Involved
Dr. Jitendra Singh, the Union Health Minister, said that the breakthrough “is a testament to Atmanirbhar Bharat in health innovation.” Patient advocacy groups like the Thrombosis Research Institute praise its focus on fairness, which helps bring people from cities and towns together.
Critics, on the other hand, urge to be careful not to get too excited about technology that hasn’t been tested yet and underline the necessity for strict multicenter research, which the team agrees with.
IIT Madras has made a breakthrough that changes the way we discover blood clots with never-before-seen accuracy.
